This website uses cookies

Read our Privacy policy and Terms of use for more information.

Your response has been recorded.

Which result would most change care over the next two years?

  • Clearer evidence on when sirolimus balloons outperform other restenosis options
  • Durable FOP outcomes with Atebrioz beyond the initial study
  • Human data showing whether PM647 safely corrects its target
  • Measurable reductions in treatment delays from medication-access AI